Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
| Autor: | Scott D. Metzler, Steve Clayton, Joseph O. Moore, Darell D. Bigner, Bonnie Toaso, Cristina Gasparetto, Anand S. Lagoo, Michael R. Zalutsky, Nelson J. Chao, Charles N. Pegram, David A. Rizzieri, Jon P. Gockerman, James E. Bowsher, R. Edward Coleman, Gamal Akabani, Elizabeth Anderson, Carlos M. DeCastro |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Pathology medicine.medical_specialty medicine.medical_treatment Biopsy Immunology Biochemistry Iodine Radioisotopes Mice Pharmacokinetics Bone Marrow Infusion Procedure Medicine Animals Humans Tissue Distribution medicine.diagnostic_test business.industry Immunotoxins Lymphoma Non-Hodgkin Patient Selection Half-life Antibodies Monoclonal Biological Transport Tenascin Cell Biology Hematology medicine.disease Lymphoma Radiation therapy medicine.anatomical_structure Toxicity Female Bone marrow Lymph Nodes Nuclear medicine business Tomography X-Ray Computed |
| Zdroj: | Blood. 104(3) |
| ISSN: | 0006-4971 |
| Popis: | We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of 131I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered activity of 1480 MBq (40 mCi), and 2 developed hematologic toxicity that required stem cell infusion. Six patients received an administered activity of 1110 MBq (30 mCi), and 2 developed toxicity that required stem cell infusion. The clearance of whole-body activity was monoexponential with a mean effective half-life of 110 hours (range, 90-136 hours) and a mean effective whole-body residence time of 159 hours (range, 130-196 hours). There was rapid uptake within the viscera; however, tumor uptake was slower. Activity in normal viscera decreased proportional to the whole body; however, tumor sites presented a slow clearance (T1/2, 86-191 hours). The mean absorbed dose to whole-body was 67 cGy (range, 51-89 hours), whereas the dose to tumor sites was 963 cGy (range, 363-1517 cGy). Despite lack of a “blocking” antibody, 1 of 9 patients attained a complete remission and 1 a partial remission. These data demonstrate this radiopharmaceutical to be an encouraging agent for the treatment of lymphoma particularly if methods to protect the normal viscera are developed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|